Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 199 publications

Activated PI3 Kinase Delta Syndrome: Molecular Pathogenesis and Emerging Therapeutics.

Activated PI3 Kinase Delta Syndrome: Molecular Pathogenesis and Emerging Therapeutics.

Journal: Cureus
Published: August 18, 2025

Dermatologic Adverse Events in Patients Receiving Duvelisib Single-Agent and Combination Therapies.

Dermatologic Adverse Events in Patients Receiving Duvelisib Single-Agent and Combination Therapies.

Journal: Clinical lymphoma, myeloma & leukemia
Published: May 23, 2025

Combination of HDAC inhibitor and PI3K inhibitor suppresses autophagy and induces apoptosis via cytoplasmic IκBα stabilization in p53-mutant diffuse large B-cell lymphoma.

Combination of HDAC inhibitor and PI3K inhibitor suppresses autophagy and induces apoptosis via cytoplasmic IκBα stabilization in p53-mutant diffuse large B-cell lymphoma.

Journal: Cell death discovery
Published: May 21, 2025

Metabolism-related ALDH1B1 acts as potential predictor and therapeutic target for primary gastrointestinal diffuse large B-cell lymphoma.

Metabolism-related ALDH1B1 acts as potential predictor and therapeutic target for primary gastrointestinal diffuse large B-cell lymphoma.

Journal: Apoptosis : an international journal on programmed cell death
Published: March 28, 2025

A long-lasting PI3Kδ inhibitor zandelisib forms a water-shielded hydrogen bond with p110δ and demonstrates sustained inhibitory effects.

A long-lasting PI3Kδ inhibitor zandelisib forms a water-shielded hydrogen bond with p110δ and demonstrates sustained inhibitory effects.

Journal: American journal of cancer research
Published: March 20, 2025

Management of Mycosis Fungoides and Sézary Syndrome With Oral Systemic Therapies.

Management of Mycosis Fungoides and Sézary Syndrome With Oral Systemic Therapies.

Journal: Journal of cutaneous medicine and surgery
Published: March 12, 2025

Real-world evidence of duvelisib and romidepsin in relapsed/refractory peripheral and cutaneous T-cell lymphomas.

Real-world evidence of duvelisib and romidepsin in relapsed/refractory peripheral and cutaneous T-cell lymphomas.

Journal: Blood advances
Published: March 10, 2025

Real-world Evidence of Duvelisib and Romidepsin in Relapsed/Refractory Peripheral and Cutaneous T-cell Lymphomas.

Real-world Evidence of Duvelisib and Romidepsin in Relapsed/Refractory Peripheral and Cutaneous T-cell Lymphomas.

Journal: Blood advances
Published: March 10, 2025

Expression Modulation of Immune Inhibitory Molecules by Small Molecule Inhibitor Drugs in Leukemic Cells of Chronic Lymphocytic Leukemia.

Expression Modulation of Immune Inhibitory Molecules by Small Molecule Inhibitor Drugs in Leukemic Cells of Chronic Lymphocytic Leukemia.

Journal: Iranian journal of pharmaceutical research : IJPR
Published: January 12, 2025

BV and beyond: how to incorporate novel agents into PTCL management.

BV and beyond: how to incorporate novel agents into PTCL management.

Journal: Hematology. American Society of Hematology. Education Program
Published: December 07, 2024

Combinatorial screen of targeted agents with the PI3K inhibitors inavolisib, alpelisib, duvelisib, and copanlisib in multi-cell type tumor spheroids.

Combinatorial screen of targeted agents with the PI3K inhibitors inavolisib, alpelisib, duvelisib, and copanlisib in multi-cell type tumor spheroids.

Journal: SLAS discovery : advancing life sciences R & D
Published: November 30, 2024

Targeting PI3K in cancer treatment: A comprehensive review with insights from clinical outcomes.

Targeting PI3K in cancer treatment: A comprehensive review with insights from clinical outcomes.

Journal: European journal of pharmacology
Published: November 16, 2024
Showing 1-12 of 199

Last Updated: 10/31/2025